Veri Seti

• ReLife study general questionnaire

  Patients with localized stage I-III renal cell cancer (n=365) completed paper-and-pencil or web-based questionnaires at 3 months (n=368), 12 months (n=317), and 24 months...

• ReLife study clinical data

  Data on tumour characteristics, treatment, complications, recurrence(s), progression and mortality were collected from medical records by data managers of the Netherlands Cancer...

• PRIDE Study questionnaire data

  In this ongoing prospective cohort study, women complete web-based questionnaires at three time points in pregnancy (at enrollment [median gestational age 10 weeks], gestational...

• ReLife study tissue samples

  Permission is available for collection of tumour blocks.

• Continuous Vital Parameters with Clinical Data of Patients Admitted to a...

  Vital parameters measured with the VisiMobile (Sotera Wireless; San Diego, CA, USA) of inpatients at Radboudumc (Nijmegen, The Netherlands). The dataset records minute-by-minute...

• POM wearables

  Wearable data of the Personalized Parkinson Project, including data obtained with a Verily watch.

• POM clinical data

  Clinical data of the Personalized Parkinson Project, including motor scores, cognitive and neuropsychiatric assessments, autonomic symptoms, sleep and quality of life.

• UroLife study general questionnaire

  Patients with non-muscle invasive bladder cancer (n=1512) completed paper-and-pencil or web-based questionnaires at 6 weeks (referring to pre-diagnosis lifestyle; n=1486) and 3...

• ReLife study quality of life questionnaire

  The EORTC QLQ-C30 was completed at 3 (n=365), 12 (n=317) and 24 months (n=279) after surgery.

• PRIDE Study blood samples

  First trimester blood samples (plasma, serum, whole blood) of ~1000 PRIDE Study participants, available for genetic and biochemical analyses. Stored at -80°C.

• UroLife study blood samples

  EDTA and heparin plasma samples were collected at 3 (n=1280) and 15 months (n=1122) after diagnosis. Heparin plasma samples have been analysed for carotenoids at 3 and 15 months...

• ReLife study abdominal CT scans

  Abdominal CT scans are availabe for n=349 patients.

• UroLife study molecular subtypes

  Molecular subtype based on immunohistrochemistry performed on tissue microarrays is available for 389 T1 NMIBC tumours.

• PRIDE Study obstetric records

  Selected clinical data from obstetric records covering the pregnancy period and puerperium. Necessitates additional consent, provided by ~70% of participants

• PRIDE Study paternal questionnaire data

  Questionnaire data focusing on paternal exposures the 3 months before conception. Completed by the biological father, <50% participation rate.

• ReLife study body composition data

  CT-based assessment of body composition is available for n=349 patients.

• PRISMA Questionnaire data

  The extensive questionnaire covers a number of potential breast cancer risk predictors such as demographics, personal characteristics, reproductive characteristics, medication,...